Ono, BMS switching to flat dosing for Opdivo in Japan

In November, the unit price of cancer drug Opdivo nivolumab from Ono Pharmaceutical Co. Ltd. (Tokyo:4528) and partner Bristol-Myers Squibb Co. (NYSE:BMY) will decrease by

Read the full 253 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE